Abstract: The present invention relates to the identification of ALMS1 as the missing player involved in the regulation of the insulin-mediated glucose uptake through GLUT4 sorting vesicles, and to the down-regulation of ALMS1 by ?PKC. Accordingly, the present invention relates to a molecule capable of preventing the binding of ?PKC on ALMS1 for use for treating or preventing diabetes, in particular type 2 diabetes. In addition, the present invention relates to a method for identifying molecule capable of preventing the binding of ?PKC on ALMS1.

Abstract: The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflammation, cirrhosis, hepatocellular carcinoma or fibrosis, especially liver fibrosis.

Abstract: The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflammation, cirrhosis, hepatocellular carcinoma or fibrosis, especially liver fibrosis.

Abstract: The present invention relates to peptides for the treatment or prevention of diabetes mellitus and associated disorders.

Abstract: The present invention relates to peptides for the treatment of diabetes and associated disorders.

Abstract: The disclosure is related to a method of treating chronic kidney disease in a subject with a melanocortin-4 receptor (MC4R) agonist, e.g., a compound of any one of Formulas (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (X), or (XI), or a pharmaceutically acceptable salt thereof (e.g., as described herein).

Abstract: The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflammation, cirrhosis, hepatocellular carcinoma or fibrosis, especially liver fibrosis.

Abstract: The present invention relates to the identification of ALMS1 as the missing player involved in the regulation of the insulin-mediated glucose uptake through GLUT4 sorting vesicles, and to the down-regulation of ALMS1 by ?PKC. Accordingly, the present invention relates to a molecule capable of preventing the binding of ?PKC on ALMS1 for use for treating or preventing diabetes, in particular type 2 diabetes. In addition, the present invention relates to a method for identifying molecule capable of preventing the binding of ?PKC on ALMS1.

Abstract: The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver fibrosis, liver inflammation, cirrhosis, or hepatocellular carcinoma.

Abstract: The present invention relates to the identification of ALMS1 as the missing player involved in the regulation of the insulin-mediated glucose uptake through GLUT4 sorting vesicles, and to the down-regulation of ALMS1 by ?PKC. Accordingly, the present invention relates to a molecule capable of preventing the binding of ?PKC on ALMS1 for use for treating or preventing diabetes, in particular type 2 diabetes. In addition, the present invention relates to a method for identifying molecule capable of preventing the binding of ?PKC on ALMS1.

Abstract: The present invention relates to peptides for the treatment or prevention of diabetes mellitus and associated disorders.

Abstract: The present invention relates to a pharmaceutical composition comprising an inhibitor of eIF2?, a compound increasing the expression and/or activity of protein BiP and/or an inhibitor of Caspase-12, preferably an inhibitor of eIF2? and a compound increasing the expression and/or activity of protein BiP. The present invention also relates to pharmaceutical compositions and methods for treating retinal degeneration related to ciliary dysfunction.

Abstract: The present invention relates to a pharmaceutical composition comprising an inhibitor of eIF2?, a compound increasing the expression and/or activity of protein BiP and/or an inhibitor of Caspase-12, preferably an inhibitor of eIF2? and a compound increasing the expression and/or activity of protein BiP. The present invention also relates to pharmaceutical compositions and methods for treating retinal degeneration related to ciliary dysfunction.

Abstract: The present invention relates to the identification of ALMS1 as the missing player involved in the regulation of the insulin-mediated glucose uptake through GLUT4 sorting vesicles, and to the down-regulation of ALMS1 by ?PKC. Accordingly, the present invention relates to a molecule capable of preventing the binding of ?PKC on ALMS1 for use for treating or preventing diabetes, in particular type 2 diabetes. In addition, the present invention relates to a method for identifying molecule capable of preventing the binding of ?PKC on ALMS1.

Abstract: The present invention relates to a pharmaceutical composition comprising an inhibitor of eIF2?, a compound increasing the expression and/or activity of protein BiP and/or an inhibitor of Caspase-12, preferably an inhibitor of eIF2? and a compound increasing the expression and/or activity of protein BiP. The present invention also relates to pharmaceutical compositions and methods for treating retinal degeneration related to ciliary dysfunction.

Abstract: A method for assembling a gas turbine engine is provided. The method comprises coupling a first turbine nozzle within the engine, coupling a second turbine nozzle circumferentially adjacent the first turbine nozzle such that a gap is defined between the first and second turbine nozzles and providing at least one spline seal including a substantially planar body. The method also comprises forming at least one catch to extend outward from the body portion of the at least one spline seal, and inserting the at least one spline seal into a slot defined in at least one of the first and second turbine nozzles to facilitate reducing leakage through said gap, such that a portion of the at least one spline seal is received within a recess defined within the turbine nozzle slot to facilitate retaining the at least one spline seal within the turbine nozzle slot.

Abstract: A method of color image processing comprises at least the following steps: the color image is converted into an intermediate image comprising components that depend solely on the H and S components of the original image in an HSV or HLS representation; the intermediate image comprising at least two components X and Y, determined by functions especially of the H component, these functions taking the same value when the H component is zero or equal to one; a new image comprising only one component is generated from the intermediate image, the component of this new image being a function of the components of the intermediate image. The disclosed method can be applied especially to the heightening of contrast in remote surveillance, and to image processing before segmentation in mobile robotics.

Abstract: A method for assembling a gas turbine engine is provided. The method comprises coupling a first turbine nozzle within the engine, coupling a second turbine nozzle circumferentially adjacent the first turbine nozzle such that a gap is defined between the first and second turbine nozzles and providing at least one spline seal including a substantially planar body. The method also comprises forming at least one retainer tab to extend outward from the body portion of the at least one spline seal, and inserting the at least one spline seal into a slot defined in at least one of the first and second turbine nozzles to facilitate reducing leakage through the gap, such that the at least one retainer tab facilitates retaining the retainer tab within the turbine nozzle slot.

Abstract: Method of color image processing to eliminate shadows and reflection A method of color image processing comprises at least the following steps: the color image is converted into an intermediate image comprising components that depend solely on the H and S components of the original image in an HSV or HLS representation; the intermediate image comprising at least two components X and Y, determined by functions especially of the H component, these functions taking the same value when the H component is zero or equal to one; a new image comprising only one component is generated from the intermediate image, the component of this new image being a function of the components of the intermediate image. The disclosed method can be applied especially to the heightening of contrast in remote surveillance, and to image processing before segmentation in mobile robotics.